申请人:Kaken Pharmaceutical Co., Ltd.
公开号:US05095016A1
公开(公告)日:1992-03-10
A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group or a R.sup.7 --CO-- group (wherein R.sup.7 is a C.sub.1-6 alkyl group, a phenyl group, a C.sub.2-6 alkenyl group which may be substituted by a phenyl group, or a C.sub.1-6 alkoxy group); R.sup.2 is a hydrogen atom, a substituted or unsubstituted C.sub.1-8 alkyl group, or a phenyl group; R.sup.3 is a hydrogen atom, and R.sup.4 is a hydroxyl group, or R.sup.3 and R.sup.4 together form a bond; each of R.sup.5 and R.sup.6 is a C.sub.1-4 alkyl group; and Y is a cyano group, a halogen atom, a nitro group, a C.sub.1-6 alkyl group, a C.sub.2-6 alkynyl group, a C.sub.1-6 alkylcarbonyl group, a C.sub.1-6 alkoxy group, a di-C.sub.1-6 alkylaminocarbonyl group, an aryl group, a C.sub.1-6 alkoxycarbonyl group, a carboxyl group or a morpholinocarbonyl group.
化合物的公式(I):##STR1## 或其药学上可接受的盐,其中:R.sup.1是氢原子,取代或未取代的C.sub.1-6烷基,C.sub.2-6烯基,C.sub.2-6炔基或R.sup.7 --CO--基团(其中R.sup.7是C.sub.1-6烷基,苯基,C.sub.2-6烯基,可被苯基取代,或C.sub.1-6烷氧基); R.sup.2是氢原子,取代或未取代的C.sub.1-8烷基或苯基; R.sup.3是氢原子,R.sup.4是羟基,或R.sup.3和R.sup.4共同形成键; R.sup.5和R.sup.6中的每一个是C.sub.1-4烷基; Y是
氰基,卤素原子,硝基,C.sub.1-6烷基,C.sub.2-6炔基,C.sub.1-6烷基羰基,C.sub.1-6烷氧基,二C.sub.1-6烷基
氨基羰基,芳基,C.sub.1-6烷氧羰基,羧基或
吗啡啶羰基。